Skip to main content

Table 2 Baseline characteristics of randomised groups

From: A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study

 

Placebo then donepezil (n = 10)

Donepezil then placebo (n = 8)

Gender

4 male, 6 female

1 male, 7 female

Handedness

10 right

3 left, 5 right

Age (years)

60.2 (7.3)

62.9 (6.0)

Disease duration (years)

3.3 (1.9)a

3.7 (1.5)

MMSE

23.9 (4.0)

22.6 (3.2)

Simple calculation

6.9 (1.4)b

7.3 (1.0)a

Number location

3.9 (2.8)

3.8 (2.9)

Letter cancellation

59.8 (21.5)

91.9 (19.7)

Dot counting

5.3 (2.6)a

5.1 (3.6)a

Digit span

13.4 (3.0)a

13.6 (4.4)a

  1. Data presented as mean (standard deviation) unless otherwise stated
  2. MMSE Mini-Mental State Examination
  3. aOne missing value
  4. bTwo missing values